Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial Authors: Nor Asiah Muhamad, Nor Soleha Mohd Dali, Nur Hasnah Maamor, Izzah Athirah Rosli, Fatin Norhasny Leman, S Maria Awaluddin, Huan Keat Chan, Rozainanee Mohd Zin, Muhammad Radzi Abu Hassan Published: 2026 ABSTRACT AbstractBackgroundHepatitis C virus (HCV) infection remains a major global health burden, contributing to chronic liver disease and significant mortality. Malaysia has implemented direct-acting antiviral (DAA) therapy to support the World Health Organization’s goal of eliminating HCV by 2030. Ravidasvir/sofosbuvir (RDV/SOF) is a potent, pan-genotypic DAA regimen with high efficacy. Yet evidence comparing time to viral load suppression between shorter and standard treatment durations remains limited. This study aimed to determine the time to HCV RNA viral load suppression for the 8-week and 12-week RDV/SOF regimens among chronic HCV patients in Malaysia and to identify factors associated with the time to suppression.MethodsThis secondary analysis utilized data from a randomized, open-label, multicenter, non-inferiority clinical trial (2016–2020) involving 321 adult patients with chronic HCV infection. Kaplan–Meier survival analysis and Cox proportional hazards regression were used to evaluate time to viral suppression (HCV RNA < 15 IU/mL) and associated predictors. The final model was stratified by baseline HCV RNA load, concomitant medications, and imprisonment risk to satisfy the proportional hazards assumption.ResultsThe median time to viral load suppression was 28 days for both treatment groups, with no significant difference in Kaplan–Meier analysis (p = 0.076). In multivariable Cox regression, patients receiving the 8-week regimen were more likely to achieve viral suppression earlier than those on the 12-week regimen (adjusted hazard ratio [aHR] = 1.29, 95% CI: 1.01–1.63, p = 0.038). Higher baseline HCV RNA load was significantly associated with delayed suppression (p < 0.001). Other demographic and clinical factors were not significant.ConclusionBoth 8-week and 12-week RDV/SOF regimens achieved rapid viral suppression, with comparable median times to viral suppression. The 8-week regimen was associated with a higher likelihood of earlier suppression; however, given the modest statistical power, this finding should be interpreted with caution. The results suggest potential as an effective alternative in Genotype 1 patients. However, given the significant treatment-by-genotype interaction, the magnitude of benefit with the shorter regimen in the predominant Genotype 3 population warrants further investigation before broad programmatic recommendations can be made.Trial registrationClinicalTrials.gov Identifier: NCT04885855 [09/05/2021].Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-026-13741-5.Keywords: Hepatitis C virus, Viral load suppression, Clinical trial, Ravidasvir/Sofosbuvir, Direct-acting antiviral Introduction Hepatitis C virus (HCV) infection has long been known as a global health challenge, causing progressive liver disease, cirrhosis, hepatocellular carcinoma, and liver-related deaths. In 2022, an estimated 50 million people were living with chronic HCV infection worldwide, with approximately 1 million new infections and about 240,000 deaths annually [1]. Despite advances in prevention and treatment, many low- and middle-income countries (LMICs) still face substantial challenges in scaling up diagnostic and therapeutic services to meet the World Health Organization (WHO) elimination goals [2]. To achieve these goals, treatment initiation and innovative public health strategies must be scaled up [3]. Malaysia has a moderate HCV burden, with more than 23,000 reported cases between 2003 and 2017 [4]. The introduction of direct-acting antivirals (DAAs) into the national program in 2018 [5] marked a major shift from interferon-based therapy, which was previously associated with modest sustained virologic response (SVR) rates, long treatment durations, and considerable adverse effects [6, 7], to shorter, highly effective, and well-tolerated regimens [3, 8]. Pan-genotypic combinations such as ravidasvir/sofosbuvir (RDV/SOF) have shown cure rates exceeding 95% across diverse populations and genotypes, supporting their use in large-scale treatment programs [3, 8]. While SVR12 remains the standard endpoint of treatment efficacy, early viral kinetics, particularly the time to achieving HCV RNA viral load suppression, offer valuable insights into regimen potency, patient response patterns, and determinants of treatment success [9, 10]. Although previous Malaysian data showed variation in early suppression times in cirrhotic and non-cirrhotic patients treated with RDV/SOF, these analyses were limited to short intervals and did not compare suppression trajectories across different treatment durations [11]. Evidence comparing the early viral response between 8-week and 12-week RDV/SOF regimens is scarce, and it remains unclear whether a shorter duration can achieve similar suppression dynamics. Understanding these differences is particularly relevant for optimizing treatment delivery, reducing costs, and supporting elimination in resource-limited settings. To address this evidence gap, the current analysis was embedded within a randomized, non-inferiority clinical trial design to evaluate whether an 8-week RDV/SOF regimen is not inferior to the standard 12-week regimen in achieving early virologic response. Therefore, this study aimed to determine the time to HCV RNA suppression among patients receiving 8-week versus 12-week RDV/SOF regimens in a multicenter clinical trial in Malaysia, and to identify demographic and clinical factors associated with the time to achieve viral load suppression. Methods Study design The parent trial was designed as a randomized, open-label, multicenter, non-inferiority study to compare the clinical performance of the 8-week and 12-week RDV/SOF regimen in Malaysia. This study is a secondary analysis of data from the parent trial. The trial was conducted at multiple Ministry of Health hospitals from March 2021 to March 2023, approved by the Malaysian Medical Research and Ethics Committee (NMRR-20-328-52925), and registered with ClinicalTrials.gov (NCT04885855). The study adhered to the Malaysian Good Clinical Practice guidelines and the Declaration of Helsinki, and was monitored by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. The trial report follows the CONSORT 2010 statement and the 102 CONSORT extension for non-inferiority and equivalence randomized trials [12]. At each hospital, a gastroenterologist served as the site investigator, while a family physician oversaw trial procedures at primary healthcare centers. All participants provided written informed consent prior to enrolment. Sample size & study population Since this is a secondary analysis, the sample size for this study was calculated in the parent trial using a non-inferiority margin of 5%, a one-sided alpha of 0.05, and 80% power. Eligible participants were (i) adults (aged 18 and above), (ii) diagnosed with chronic HCV infection (any HCV genotype), (iii) had a body mass index (BMI) between 18 and 35 kg/m², (iv) HIV-negative or had well-controlled HIV (CD4 ≥ 500 cells/µL, or ≥ 100 cells/µL on stable antiretroviral therapy for ≥ 6 months), and (v) were either drug-free status or stable adherence to opioid substitution therapy (OST). The exclusion criteria included (i) cirrhosis diagnosed by non-invasive biomarkers, (ii) clinical features of hepatic decompensation (ascites, variceal bleeding, spontaneous bacterial peritonitis, or hepatic encephalopathy), (iii) laboratory findings showing severe liver enzyme elevation (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 10 times the upper limit of normal), (iv) hepatitis B coinfection (hepatitis B surface antigen (HBsAg) positive), and (v) previous exposure to any NS5A inhibitor. A total of 473 eligible patients were randomized 1:1 to receive either an 8-week or 12-week RDV/SOF regimen using a web-based randomization tool [13] by a statistician. Due to the nature of treatment duration, blinding of investigators and participants was not feasible. Participants assigned to the 8-week group attended study visits at baseline and at weeks 1, 4, and 8 (end of treatment), followed by post-treatment visits at weeks 4, 12, and 24. Participants in the 12-week group adhered to the same visit schedule but received a 12-week treatment duration, with an end-of-treatment assessment at week 12. Of the 473 randomized participants, 321 were included in the final analysis (Fig. 1). Participants with incomplete treatment, withdrawal of consent, or loss to follow-up resulting in missing time-to-event information were excluded. To assess potential selection bias due to participant exclusion, baseline characteristics of included (n = 321) and excluded participants (n = 152) were compared (Supplementary Table 1). Most demographic and clinical variables were comparable between the two groups (p > 0.05). However, significant differences were observed for HCV genotype distribution and baseline HCV RNA level (both p < 0.001). The excluded group contained a higher proportion of other genotypes, whereas the included cohort had a greater proportion of participants with high baseline viral load (≥ 800,000 IU/mL). These variables were accounted for in the multivariable Cox model, where genotype was included as a covariate and baseline viral load was handled through model stratification. The CONSORT flow chart of 473 patients randomized into two groups (8-week and 12-week) for time-to-event analysis Outcome measures The primary outcome was time to HCV RNA viral load suppression, defined as the number of days from treatment initiation to achieving HCV RNA < 15 IU/mL. The viral load threshold reflected the lower limit of quantification of the diagnostic assay used across study sites. The secondary outcome was to identify demographic and clinical factors associated with the time to viral load suppression. Data collection Baseline sociodemographic variables included sex, age, ethnicity, marital status, employment status, and education level. Baseline clinical characteristics included HCV genotype, baseline HCV RNA level, HIV coinfection, use of concomitant medications, relevant medical history, and exposure to known risk factors such as injection drug use, imprisonment, and invasive medical procedures. HCV RNA levels were measured at all scheduled visits using standard quantitative assays available at each participating center. After providing written informed consent, individuals with a prior positive HCV antibody test or detectable HCV RNA underwent quantitative HCV RNA measurement and genotyping. HCV RNA levels were quantified using either the Abbott m2000 system or the Alinity m HCV assay (Abbott Molecular, Chicago, IL, USA). There were 11 pathology laboratories involved in conducting the test, including nine (81.8%) that used the Abbott m2000 system and two (18.2%) that used the Alinity m HCV assay. Since randomization was performed at the participant level using a web-based tool independent of the site, and site-level assay use was fixed throughout the study period, the distribution of assay platforms across treatment arms was comparable (m2000 system: 8-week n = 131, 12-week n = 128; Alinity m HCV assay: 8-week n = 21, 12-week n = 25). Both assays share an identical lower limit of quantification of 15 IU/ml, minimizing the potential for differential measurement bias. HCV genotyping was performed using either the Roche Cobas 4800 Molecular Analyzer (Roch, Basel, Switzerland) or the Abbott RealTime HCV Genotype II assay (Abbott Molecular, Chicago, IL, USA). All participating laboratories were under the Ministry of Health Malaysia and were certified by External Quality Assessment Services (EQAS), as an ISO 17043-accredited program for performance verification. Statistical analysis All analyses were conducted using R Statistical Software [14]. Treatment adherence was estimated using pill-count methodology based on the number of remaining tablets recorded at study visits. Adherence percentage was calculated as the proportion of expected tablets taken over the treatment duration. Differences in adherence between treatment groups were assessed using the Mann-Whitney U test. In the time-to-event analysis, the event of interest was viral load suppression (HCV RNA < 15 IU/mL). Participants who did not achieve suppression by their last available viral load measurement were censored at that time. Kaplan-Meier survival curves were constructed to estimate time to viral suppression. Differences across treatment groups and baseline characteristics were assessed using the log-rank test. Cox proportional hazards regression analysis was performed to identify factors associated with time to HCV RNA suppression. Univariate Cox proportional hazards regression models were used to examine the association between baseline characteristics and time to viral suppression. Variables with p-values < 0.10 in the univariate analysis were considered for inclusion in multivariable models. The proportional hazards (PH) assumption was assessed using Schoenfeld residual tests and graphical inspection of scaled Schoenfeld residual plots. Evidence of violation of the proportional hazard assumption was observed for baseline HCV RNA level (p = 0.0006) and concomitant medication use (p = 0.032). The Schoenfeld residual plots for these variables showed non-horizontal trends over time, suggesting that their effects on viral suppression were not constant during follow-up. Imprisonment history showed a borderline result in the Schoenfeld test (p = 0.074), with mild fluctuations in the residual plot but no strong systematic trend. To address potential non-proportional hazards, baseline HCV RNA level, concomitant medication use, and imprisonment were included as stratification factors in the Cox proportional hazards model, allowing the baseline hazard functions to vary across strata while estimating common hazard ratios for the remaining covariates. The final stratified multivariable Cox regression model was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for predictors of time to HCV RNA suppression. Statistical significance was defined as p < 0.05. A post hoc power analysis for the primary outcome was conducted using the observed sample sizes (nE = 160, nC = 161), event probabilities (pE = 0.994, pC = 0.988), and the estimated hazard ratio (HR = 1.29) from the final stratified Cox proportional hazards model. Power estimation was performed using the ‘powerSurvEpi’ package in R [15]. The resulting statistical power to detect an HR of 1.29 at a two-sided alpha of 0.05 was 61.8%, indicating that the study was underpowered relative to the conventional 80% threshold. Results Patient characteristics A total of 321 participants were included in this analysis, with 160 (49.8%) assigned to the 8-week RDV/SOF regimen group and 161 (50.2%) to the 12-week treatment group. Participant enrolment began on August 9, 2022, and the final participant was recruited on March 22, 2023. The last study visit was completed on November 27, 2023. Baseline sociodemographic characteristics are summarized in Table 1. The study population was predominantly male (92.8%) with a mean age of 44.5 ± 10.0 years (range 18–69 years). Most participants were Malays (79.1%), employed (64.8%), and had completed secondary education (78.2%). No major differences were observed between treatment groups across sociodemographic variables. Baseline characteristics were generally balanced between groups, supporting the integrity of the randomized non-inferiority comparison. Table 1Sociodemographic characteristics of chronic Hepatitis C patients in the 8-week and 12-week treatment groups. (N = 321)Overall(N = 321)8-week Group(n = 160)12-week Group(n = 161)p-valuea Sex 0.395 Male298 (92.8)151 (94.4)147 (91.3) Female23 (7.2)9 (5.6)14 (8.7) Age, mean ± SD 44.5 ± 10.043.6 ± 10.345.4 ± 9.70.096b Ethnicity 0.878 Malay254 (79.1)127 (79.4)127 (78.9) Chinese33 (10.3)16 (10.0)17 (10.6) Indian8 (2.5)3 (1.9)5 (3.1) Others26 (8.1)14 (8.7)12 (7.5) Marital status 0.418 Single116 (36.1)56 (35.0)60 (37.3) Married161 (50.2)78 (48.7)83 (51.6) Others44 (13.7)26 (16.3)18 (11.2) Occupation 0.297 Unemployed77 (24.0)35 (21.9)42 (26.1) Employed208 (64.8)103 (64.4)105 (65.2) Others36 (11.2)22 (13.8)14 (8.7) Education level 0.845 Primary45 (14.0)24 (15.0)21 (13.0) Secondary251 (78.2)123 (76.9)128 (79.5) Tertiary25 (7.8)13 (8.1)12 (7.5)a Pearson’s Chi-squared test, significant at p < 0.05b Independent t-test, significant at p < 0.05 Sociodemographic characteristics of chronic Hepatitis C patients in the 8-week and 12-week treatment groups. (N = 321) a Pearson’s Chi-squared test, significant at p < 0.05 b Independent t-test, significant at p < 0.05 Baseline clinical characteristics of the participants are presented in Table 2. Many of the patients were infected with HCV genotype 3 (60.1%), followed by genotype 1 (31.5%). A total of 204 (63.6%) had a baseline HCV RNA ≥ 800,000 IU/mL. HIV coinfection was present in 21 participants (6.5%). Most participants (82.9%) reported concomitant medication use, and nearly all (97.8%) had at least one identifiable HCV risk factor, most commonly injection drug use (76.3%). Table 2Baseline clinical characteristics of chronic Hepatitis C patients in the 8-week and 12-week treatment groups. (N = 321)Overall(N = 321)8-week Group(n = 160)12-week Group(n = 161)p-valueb HCV genotype 0.679 Genotype 1101 (31.5)54 (33.8)47 (29.2) Genotype 3193 (60.1)93 (58.1)100 (62.1) Other genotypesa27 (8.4)13 (8.1)14 (8.7) Baseline HCV RNA (IU/mL) 0.513 < 800,000117 (36.4)55 (34.4)62 (38.5) ≥ 800,000204 (63.6)105 (65.6)99 (61.5) HIV coinfection 0.662 No300 (93.5)151 (94.4)149 (92.5) Yes21 (6.5)9 (5.6)12 (7.5) Concomitant medication 0.007 No55 (17.1)37 (23.1)18 (11.2) Yes266 (82.9)123 (76.9)143 (88.8) Medical history 0.909 None259 (80.7)130 (81.2)129 (80.1) Any medical history62 (19.3)30 (18.8)32 (19.9) Obesity19 (5.9)10 (6.2)9 (5.6)0.989 Diabetes18 (5.6)7 (4.4)11 (6.8)0.475 Psychiatry illness12 (3.7)5 (3.1)7 (4.3)0.777 NAFLD9 (2.8)4 (2.5)5 (3.1)1.000 Exposed to risk factors 1.000 None7 (2.2)3 (1.9)4 (2.5) Any risk factor314 (97.8)157 (98.1)157 (97.5) Injection drug use245 (76.3)120 (75.0)125 (77.6)0.671 Imprisonment165 (51.4)83 (51.9)82 (50.9)0.954 Invasive medical procedures96 (29.9)50 (31.2)46 (28.6)0.688a mixed-genotype, or indeterminate genotypeb Pearson’s Chi-squared test, significant at p < 0.05 (bold) Baseline clinical characteristics of chronic Hepatitis C patients in the 8-week and 12-week treatment groups. (N = 321) a mixed-genotype, or indeterminate genotype b Pearson’s Chi-squared test, significant at p < 0.05 (bold) Treatment adherence, measured using the pill-count method, was available only for the 321 participants who completed follow-up. Adherence data were not available for the 152 excluded participants because incomplete treatment attendance precluded reliable recording of tablet returns. Among included participants, adherence was uniformly high, with a median of 100% (IQR 100–100) in both groups, while the overall mean was 99.1%. A total of 31 participants (9.7%) had measured adherence below 95%. No statistically significant difference in adherence was observed between treatment groups (p = 0.399). Time to HCV RNA viral load suppression In the analysis of 321 patients with chronic hepatitis C treated with RDV/SOF, the time to achieving HCV RNA < 15 IU/mL ranged from 6 to 254 days. Overall, 50% of patients achieved viral suppression at 28 days (Fig. 2). Log-rank analysis revealed no significant difference (p = 0.076) in the time to viral suppression between the 8-week and 12-week treatment groups (Fig. 3). The median time to suppression was 28 days for both treatment groups. The comparable median suppression times are consistent with a non-inferiority trial framework, suggesting no meaningful delay in early virologic response with the 8-week regimen. Additionally, only 11 patients (6.9%) in the 8-week group and 26 patients (16.1%) in the 12-week group had not achieved viral load suppression by 60 days (2 months) after treatment initiation. Kaplan-Meier curve of the time to HCV RNA viral load suppression (< 15 IU/mL) among chronic Hepatitis C patients treated with RDV/SOF. The dashed line presents the median time Kaplan-Meier curve of the time to HCV RNA viral load suppression (< 15 IU/mL) between 8-week and 12-week treatment groups. The dashed line presents the median time Time to HCV RNA viral load suppression across sociodemographic and baseline clinical characteristics Log-rank analyses also showed no significant differences in the time to viral suppression across sociodemographic characteristics, including sex (p = 0.131), ethnicity (p = 0.168), marital status (p = 0.386), occupation (p = 0.401), and education level (p = 0.761). Similarly, no differences were observed across baseline clinical characteristics, including HCV genotype (p = 0.224), presence of HIV coinfection (p = 0.933), use of concomitant medications (p = 0.438), medical history (p = 0.117), exposure to any risk factors (p = 0.704), history of injection drug use (p = 0.883), imprisonment (p = 0.217), or exposure to invasive medical procedures (p = 0.105). The only significant difference observed was for baseline HCV RNA load (p < 0.0001) (Fig. 4). Kaplan-Meier curve of the time to HCV RNA viral load suppression (< 15 IU/mL) between HCV RNA load at baseline groups. The dashed lines present the median times Cox proportional hazards regression analysis Univariate Cox regression results are presented in Table 3. Several variables showed potential associations (p < 0.10) with time to suppression. The treatment group showed that patients in the 8-week group had a higher rate of suppression (HR = 1.23, 95% CI 0.98–1.54, p = 0.072). Among sociodemographic characteristics, female participants demonstrated a trend toward faster suppression (HR = 1.46, 95% CI 0.95–2.24, p = 0.082). Among baseline clinical characteristics, high viral load (≥ 800,000 IU/mL) was strongly associated with delayed suppression (HR = 0.51, 95% CI 0.41–0.65, p < 0.001). Other sociodemographic and clinical variables, including HCV genotype, HIV coinfection, concomitant medication, medical history, and risk factors, did not show significant associations. Treatment group, sex, and all baseline clinical characteristics were subsequently included in the multivariate Cox regression model. Table 3Univariate Cox proportional hazards regression analysis of factors associated with time to HCV RNA suppressionHR95% CIp-value Treatment group 12-week group (ref)1.00-- 8-week group1.230.98–1.540.072* Sex Male (ref)1.00-- Female1.460.95–2.240.082* Age a 0.990.98–1.000.148 Ethnicity Malay (ref)1.00-- Chinese1.250.87–1.800.227 Indian1.750.86–3.550.120 Others1.370.91–2.060.126 Marital status Single (ref)1.00-- Married1.100.87–1.400.429 Others0.860.61–1.220.404 Occupation Unemployed (ref)1.00-- Employed0.840.65–1.100.207 Others0.760.51–1.130.177 Education level Primary (ref)1.00-- Secondary0.960.70–1.320.788 Tertiary0.850.52–1.400.521 HCV genotype Genotype 1 (ref)1.00-- Genotype 31.220.95–1.550.114 Other genotypesb1.250.81–1.910.313 Baseline HCV RNA (IU/mL) < 800,000 (ref)1.00-- ≥ 800,0000.510.41–0.65< 0.001* HIV coinfection No (ref)1.00-- Yes0.990.64–1.550.972 Concomitant medication No (ref)1.00-- Yes0.890.66–1.190.435 Medical history None (ref)1.00-- Any medical history1.230.93–1.620.152 Exposed to risk factors None (ref)1.00-- Any risk factor0.830.39–1.750.618 Injection drug use0.950.73–1.230.705 Imprisonment0.850.68–1.070.161 Invasive medical procedures0.830.65–1.060.130HR hazard ratio; CI confidence intervala continuous variable* significant at p < 0.1 Univariate Cox proportional hazards regression analysis of factors associated with time to HCV RNA suppression HR hazard ratio; CI confidence interval a continuous variable * significant at p < 0.1 In the multivariable Cox regression model, baseline HCV RNA load, concomitant medication use, and imprisonment history violated the proportional hazards assumption based on Schoenfeld residuals tests and were therefore included as stratification variables. After stratification, the model satisfied the PH assumption (Table 4). In the stratified multivariable Cox model, the treatment group was significantly associated with time to suppression. Patients in the 8-week group had a significantly higher hazard of achieving HCV RNA suppression than those in the 12-week group (aHR = 1.29, 95% CI 1.01–1.63, p = 0.038). This difference emerged after adjustment for clinical characteristics and stratification by variables that violated the proportional hazards assumption (baseline HCV RNA load, concomitant medication use, and imprisonment). In contrast, the unadjusted Kaplan–Meier analysis showed no statistically significant difference between treatment groups. Exposure to invasive medical procedures was associated with a lower hazard of achieving viral suppression (aHR = 0.75, 95% CI 0.57–0.99, p = 0.040). Sex, HCV genotype, and medical history were not significantly associated with time to suppression. Table 4Multivariate Cox proportional hazards regression analysis of factors associated with time to HCV RNA suppressionaHR95% CIp-value Treatment group 12-week group (ref)1.00-- 8-week group1.291.01–1.630.038* Sex Male (ref)1.00-- Female1.480.88–2.490.137 HCV genotype Genotype 1 (ref)1.00-- Genotype 31.140.87–1.480.348 Other genotypesa1.160.72–1.850.545 HIV coinfection No (ref)1.00-- Yes1.010.60–1.680.986 Medical history None (ref)1.00-- Any medical history1.120.83–1.510.460 Exposed to risk factors None (ref)1.00-- Any risk factor0.990.44–2.220.975 Injection drug use0.990.71–1.390.973 Invasive medical procedures0.750.57–0.990.040*aHR adjusted hazard ratio; CI confidence interval* significant at p < 0.05Model stratified by baseline HCV RNA load, concomitant medication, and risk factor (imprisonment) to account for non-proportional hazards Multivariate Cox proportional hazards regression analysis of factors associated with time to HCV RNA suppression aHR adjusted hazard ratio; CI confidence interval * significant at p < 0.05 Model stratified by baseline HCV RNA load, concomitant medication, and risk factor (imprisonment) to account for non-proportional hazards Post-stratification Schoenfeld residual p-values for all covariates remaining in the final model were computed to confirm that the PH assumption was satisfied after stratification (Supplementary Table 3). All individual covariates yielded non-significant p-values (range from 0.13 to 0.95). The global test was likewise non-significant (χ² = 6.508, df = 9, p = 0.69). providing no evidence of a violation of the PH assumption in the stratified model. Subgroup analyses Subgroup analyses were conducted to evaluate whether the treatment effect differed by HCV genotype and baseline viral load. Only 294 of 321 patients (91.6%) with Genotype 1 or 3 were included in the analysis comparing treatment groups by HCV genotype (Genotype 1 vs. Genotype 3) using a Cox proportional hazards model. Among patients with Genotype 1 infection (n = 101), the 8-week regimen was associated with a significantly higher rate of viral suppression compared with the 12-week regimen (HR 1.70, 95% CI 1.11–2.60, p = 0.015), indicating faster suppression with the shorter course. In contrast, among Genotype 3 patients (n = 193), the HR for the 8-week versus 12-week regimen was 0.95 (95% CI: 0.72–1.26, p = 0.728), indicating no evidence of a difference in time to viral suppression between treatment groups. A statistically significant interaction between treatment group and genotype was observed (interaction HR 0.61, 95% CI 0.37–0.99, p = 0.047), confirming that the effect of treatment duration on time to viral suppression differed significantly by genotype. The 27 patients with other, mixed, or indeterminate genotypes were excluded from this genotype-stratified analysis because their heterogeneous classification precludes meaningful estimation of genotype-specific effects. Another interaction analysis between treatment group and baseline HCV RNA level (< 800,000 vs. ≥ 800,000 IU/mL) was also performed. Baseline high viral load was independently associated with a longer time to viral suppression (HR 0.49, 95% CI 0.36–0.68, p < 0.001). However, there was no significant interaction between treatment group and baseline viral load (interaction HR 1.06, 95% CI 0.67–1.67, p = 0.813), indicating that the effect of the 8-week regimen on time to suppression was consistent across viral load strata. Sustained virologic response (SVR12) Sustained virologic response at 12 weeks post-treatment (SVR12) data were available for all 321 per-protocol participants. SVR12 was achieved in 280 of 321 patients (87.2% [per-protocol]). Among patients receiving the 8-week regimen, 139 of 160 (86.9%) achieved SVR12, compared with 141 of 161 (87.6%) in the 12-week group (risk difference − 0.7%, 95% CI (Newcombe hybrid score): -8.0% to + 6.6%). There was no statistically significant difference in SVR12 rates between treatment groups (p = 0.983). As the upper bound of the 95% CI (+ 6.6% in favor of 12-week) exceeded the pre-specified non-inferiority margin of 5%, formal non-inferiority of the 8-week regimen with respect to SVR12 could not be established in this per-protocol cohort. Discussion This study evaluated the time to HCV RNA viral load suppression among patients with chronic hepatitis C receiving 8-week and 12-week ravidasvir/sofosbuvir (RDV/SOF) regimens in Malaysia. Overall, both treatment durations achieved rapid viral suppression. The 8-week regimen was associated with a modestly higher adjusted hazard of achieving viral suppression compared with the 12-week regimen, although the precision of this estimate is limited and should be interpreted with caution, given the modest power of the study. However, the median time to suppression was identical between groups, suggesting that while statistical differences were observed after adjustment, the clinical impact of treatment duration on early viral kinetics may be limited. This discrepancy between Kaplan-Meier and multivariable Cox regression findings likely reflects the influence of baseline covariates, particularly viral load, which was the strongest predictor of time to suppression. The post hoc power analysis estimated approximately 62% power to detect an HR of 1.29 at a two-sided alpha of 0.05, falling below the conventional 80% threshold. This suggests the study was underpowered for the primary time-to-event comparison. Non-significant findings from the Kaplan-Meier analysis should therefore be interpreted cautiously, as they may reflect limited statistical power rather than true equivalence between treatment durations. The adjusted Cox regression finding of an aHR of 1.29 (95% CI: 1.01–163) should similarly be interpreted in the context of this modest power, and confirmation in larger prospective studies is warranted. The observation that half of the patients achieved viral suppression within the first month of therapy is consistent with the known potency of pan-genotypic DAAs [7, 16–18]. Previous studies of sofosbuvir-based regimens, including ledipasvir/sofosbuvir, also reported rapid viral decline and comparable early suppression between 8-week and 12-week courses [19–21]. Our findings align with these reports and reinforce the biological plausibility that an 8-week RDV/SOF regimen may yield virologic responses comparable to those achieved with the conventional 12-week regimen. The SVR12 rate of 87.2% observed in this cohort is lower than the rates exceeding 95% reported in several registration trials of RDV/SOF [22, 23]. This difference may be attributable to the composition of our study population, which is that genotype 3 accounted for 60.1% of participants, a genotype historically associated with attenuated response to some NS5A inhibitor-containing regimens [24, 25]. 63.6% of patients had high baseline viral loads (≥ 800,000 IU/ml), and the cohort included individuals with HIV co-infection, history of injection drug use, and prior imprisonment. These characteristics reflect real-world Malaysian clinical practice rather than the enriched populations typically enrolled in registration trials. Baseline HCV RNA level remained a key determinant of treatment response, with higher viral loads associated with delayed suppression. This finding is consistent with well-established evidence showing slower virologic decline in patients with higher pretreatment HCV RNA levels [26, 27]. Subgroup analyses revealed a statistically significant treatment-by-genotype interaction, indicating that the effect of treatment duration on time to viral suppression differed between patients with Genotype 1 and Genotype 3. The earlier time to viral suppression with the 8-week regimen was evident among Genotype 1 patients, but was attenuated and not statistically significant among Genotype 3 patients. This is clinically important, as Genotype 3 accounts for 60.1% of the cohort and has been associated with less favorable treatment responses to certain DAA regimens [24, 25]. The practical implication is that the time-to-suppression advantage of the 8-week RDV/SOF regimen may be most pronounced in Genotype 1 patients, while Genotype 3 patients appear to achieve comparable suppression timing regardless of treatment duration. This interaction should be confirmed in future prospective studies with larger genotype-specific sample sizes. An additional finding of interest was the association between exposure to invasive medical procedures and a lower hazard of achieving viral suppression, indicating a longer time to viral clearance. This observation may reflect underlying clinical complexity among patients with such exposure. In the Malaysian healthcare setting, individuals undergoing invasive procedures such as surgical interventions, hemodialysis, or repeated hospital-based treatments often have coexisting comorbidities or more frequent healthcare contact, which may influence immune response and treatment dynamics [28]. Furthermore, such patients may represent a subgroup with longer-standing or more clinically complex infections, which could contribute to slower viral kinetics [29]. Differences in transmission pathways and patient profiles compared to other high-risk groups, such as people who inject drugs, may also play a role. Nevertheless, given the observational nature of this association, residual confounding cannot be excluded, and this finding should be interpreted with caution. Although treatment adherence was high and comparable between the 8-week and 12-week groups in this study, the relationship between treatment duration and adherence remains clinically important. Shorter treatment regimens are generally associated with improved adherence due to reduced pill burden, shorter duration of commitment, and lower risk of treatment fatigue [30]. This is particularly relevant in populations with complex social and behavioral factors, including individuals with a history of injection drug use or incarceration, which are well-represented in the Malaysian HCV population [31]. The uniformly high adherence observed in this study likely reflects the structured monitoring and follow-up inherent to a clinical trial setting and may not fully represent routine clinical practice. In real-world settings, where adherence support may be less intensive, shorter regimens could offer a practical advantage by improving treatment completion rates and facilitating large-scale implementation of HCV elimination programs. Programmatically, shorter regimens may offer advantages, including improved adherence, reduced clinic visits, and lower treatment costs, which are key priorities for achieving the WHO elimination goal by 2023 [32, 33]. These efficiencies are particularly important for settings like Malaysia that aim to scale up DAA access under budget constraints [34]. However, the clinical relevance of a modest difference in suppression hazard remains unclear, especially since median suppression times were identical. In the context of a non-inferiority framework, the similarity in suppression kinetics strengthens the rationale for adopting shorter RDV/SOF regimens where feasible, particularly in high-burden settings aiming to maximize treatment capacity. Study limitations This study has some limitations that should be acknowledged. First, a secondary analysis of an existing clinical trial, this study was not originally powered to detect differences in early viral suppression between treatment durations, which may limit the sensitivity of the comparative findings. However, time to suppression was not a pre-specified non-inferiority endpoint; thus, the findings should be interpreted alongside the primary non-inferiority outcomes of the parent trial. Second, a substantial proportion of randomized participants (32%) were excluded due to incomplete treatment measurements. Comparison between included and excluded participants showed differences in HCV genotype distribution and baseline viral load. Although these variables were accounted for in the multivariable analysis, the potential for selection bias cannot be completely excluded. Third, a critical limitation concerns the measurement and interpretation of treatment adherence. Because adherence was estimated using the pill-count method, it is subject to overestimation, as returned tablet counts cannot confirm whether all dispensed medication was actually consumed. More importantly, adherence data were inherently unavailable for the 32% of randomized participants who were excluded due to incomplete treatment. These individuals most likely could not contribute the pill-count data. The near-ceiling adherence (median 100%, IQR 100–100) observed in the included cohort, therefore, reflects a selected population and cannot be generalized to all 473 randomized participants. This systematic missingness means that adherence as a potential confounder cannot be fully excluded, and the reported adherence figures should be interpreted with this selection caveat in mind. Additionally, comparison between included and excluded participants (Supplementary Table 2) revealed two further imbalances that deserve acknowledgment. Excluded participants had a significantly higher prevalence of diabetes (13.2% vs. 5.6%, p = 0.008), suggesting that patients with metabolic comorbidities were more likely to be lost to follow-up or have incomplete treatment data. Because insulin resistance and hepatic metabolic dysfunction associated with diabetes may influence viral kinetics and treatment response, our findings may not generalize fully to HCV patients with diabetes. Furthermore, excluded participants had a substantially higher proportion of other, mixed, or indeterminate genotypes (~ 39.5% vs. 8.4%), indicating that genotype uncertainty was a strong predictor of non-completion. Consequently, the results of this study apply most reliably to patients with confirmed Genotype 1 or 3 infection. Finally, variability in laboratory assays, instrumentation, and site-level clinical practices across participating centers may have introduced measurement heterogeneity in viral load assessment. Collectively, these limitations underscore the need for larger, prospectively designed future studies to address the study findings. Conclusion In conclusion, both 8-week and 12-week RDV/SOF regimens achieved rapid viral suppression among chronic HCV patients in Malaysia. Adjusted analyses indicated that the 8-week regimen was associated with an earlier likelihood of suppression, supporting its potential as an effective alternative for patients with Genotype 1, although confirmation in adequately powered studies is needed. However, given a significant treatment-by-genotype interaction, the magnitude of benefit with the shorter regimen in the predominant Genotype 3 population warrants further investigation before broad programmatic recommendations can be made. Ultimately, further research incorporating cost-effectiveness analyses is needed for future clinical and policy discussions on optimizing treatment duration within national HCV programs. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements We would like to thank the Director-General of Health Malaysia for the permission to publish this study. We also want to thank Dr. Isabella Andrieux-Meyer (DNDi) and Pharco Pharmaceuticals for their support of this study, and all healthcare personnel who contributed to it. Abbreviations Adjusted hazard ratio Alanine aminotransferase Aspartate aminotransferase Body mass index Confidence Intervals Consolidated Standards of Reporting Trials Direct-Acting Antivirals Hepatitis B surface antigen Hepatitis C Virus Human Immunodeficiency Virus Hazard ratio International Units per milliliter Low- and middle-income countries National Pharmaceutical Regulatory Agency Opioid substitution therapy Proportional hazards Ravidasvir/Sofosbuvir Ribonucleic acid Sustained Virologic Response Sustained Virologic Response at 12 weeks World Health Organization Author contributions NAM and NSMD analyzed the data and wrote the first draft of the manuscript. NHM, IAR, and FNL analyzed and interpreted the data. SMA and HKC performed data collection and cleanup. RMZ and MRAH supervised the study and reviewed the data. All authors have read and approved the final manuscript. Funding This study was funded by the Ministry of Health Malaysia (NMRR-20-328-52925). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This trial was approved by the Malaysian Medical and Research Ethics Committee (NMRR-20-328-52925). The study adhered to the Malaysian Good Clinical Practice guidelines and the Declaration of Helsinki, and was monitored by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. All patients consented prior to the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Nor Asiah Muhamad and Nor Soleha Mohd Dali Co-first authors. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.